New Jersey § 24:6e-6

§ 24:6e-6.

a. The department shall prepare a list of interchangeable drug products. This list shall be periodically reviewed in accordance with a schedule of and procedure

for such review as shall be established by the department . In development of the list, distinctions shall be made when: (1) evidence of bioequivalence

is considered critical and when it is not; (2) when levels of toxicity are considered

critical and when they are not. The list may include interchangeable drug products used by the United States Government

and its agencies, where the government or such agency has established the reliability

of the drug products interchanged. b. No drug products shall be included in such list until after a public hearing has

been held thereon after at least 20 days’ notice. Such notice shall be mailed to every drug company that is authorized to do business

in the State of New Jersey and to all persons who have made a timely request of the department for advance notice of its public hearings and shall be published in the New Jersey

Register. c. Manufacturers shall, upon the request of the department , be required to submit any information in their files that relates manufacturing

processes and in vivo and in vitro tests to the bioavailability of any drug product. This requirement shall also apply to technical information obtained during research

related to the development of new drug products, even when such information bears

only an indirect relationship to the final dosage form. The department shall not make such information public when there is a proprietary interest on the

part of the manufacturer. d. Any manufacturer of drug products shall have the right to request the department to evaluate its drug products for the purpose of inclusion on the list of interchangeable

drug products, or to request that the department consider removal of any drug product from the list. Any such request shall be accompanied by such information as the department shall require, and any drug product involved shall be evaluated in the same manner

and shall be subject to the same procedures and requirements as all other drug products

evaluated by the department for inclusion on or removal from the list. e. Prior to any drug product being approved by the department , the manufacturer shall be required to demonstrate that it has complied with the

standards set forth in the Current Good Manufacturing Practices of Title 21 U.S.C. 1 or in such standards relating to drug manufacturing practices as may be promulgated

by the department from time to time and must show evidence of a satisfactory inspection by the Federal

Food and Drug Administration or the department . f. The department shall distribute copies of the list of interchangeable drug products and revisions

thereof and additions thereto among physicians and other authorized prescribers and

licensed pharmacists, and shall supply a copy to any person upon request, upon payment

of the price established by the department . g. The department shall be authorized to adopt reasonable rules and regulations, in accordance with

the provisions of the “Administrative Procedure Act,” P.L.1968, c. 410 ( C.52:14B-1 et seq. ) , to carry out its functions and duties under this act and to effectuate its purposes. 1

21 U.S.C.A. § 360d.